SCHEMBL24028384

SCHEMBL24028384

Cc1cccc(C)c1-c1cc(CO)c(Cl)cc1F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.40
TAAR1 Q96RJ0 1/20 0.34
S1PR1 P21453 4/20 0.34
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
S1PR4 O95977 1/20 0.33
PPARG P37231 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MYC P01106 1/20 0.33
FFAR1 O14842 2/20 0.32
FFAR4 Q5NUL3 2/20 0.32
PDK2 Q15119 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
P2RX7 Q99572 1/20 0.32
PTGS1 P23219 2/20 0.31
PTGS2 P35354 2/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30212987 0.74 PDE2A (0.40) MYCPTGS1PTGS2
SCHEMBL12577815 0.73 GRIA1 (0.42) S1PR1PDCD1CD274S1PR4FFAR1
SCHEMBL12577746 0.73 CD274 (0.43) S1PR1PDCD1CD274FFAR1FFAR4
SCHEMBL12577894 0.72 GCGR (0.46) PDCD1CD274FFAR1FFAR4
SCHEMBL2026166 0.72 CYP4F2 (0.41) S1PR1S1PR4MYCFFAR1
SCHEMBL25584446 0.72 SHBG (0.34) MAPK14S1PR1
SCHEMBL24028007 0.72 ALDH1A1 (0.39) MYCMEN1KMT2APTGS1PTGS2
SCHEMBL12577883 0.71 PDCD1 (0.46) TAAR1PDCD1CD274MYCFFAR1
SCHEMBL3824032 0.71 POLB (0.33) TAAR1
SCHEMBL24028383 0.71 GAA (0.42) MYCPDK2MEN1KMT2APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 MAPK14 2082/4885TAAR1 896/4885S1PR1 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.